About RX Tesa

What RX Tesa is

RX Tesa is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The format is deliberate: a shadowless data sheet that logs each trial figure to its source, draws the GHRH-receptor cascade as the stepped chain it actually is, and marks the FDA-approval boundary exactly where it stops. The aim is a record a reader can scan and verify, not a sales page.

What the "RX" means here

The "RX" and "Tesa" in the domain name are editorial framing — a position this publisher occupies relative to the literature, the stark prescription-record register of a data sheet. They are not a claim that this site dispenses, prescribes, or fills anything. There is no pharmacy here, no counter, no checkout. We hold no physical address, phone line, or clinical staff, and we do not offer treatment, consultation, or prescription services of any kind.

Tesamorelin itself is a prescription drug approved only for HIV-associated lipodystrophy; research-grade material sold for laboratory use is a different thing entirely, and this site describes the published science rather than directing anyone toward a product.

How we handle the evidence

Every quantitative claim on this site is tied to a numbered citation in the full reference list. When the literature is precise — visceral fat -15.2% at 26 weeks ^[1], IGF-1 +181 ug/L in healthy men ^[4], a non-clinical half-life of 21-45 minutes in dogs ^[8] — we state it precisely. When it is limited — non-HIV efficacy untested in large trials, long-term oncologic data sparse — we say that plainly rather than filling the gap. We do not extrapolate beyond what was measured, and we keep the approved indication and the off-label boundary visible throughout.

Why the format is so plain

The brutalist data-sheet look is a deliberate fit to the subject. Tesamorelin's story is a stack of hard, quotable facts — a molecular weight, an approval date, a single indication, a set of trial percentages — and a layout that renders each figure as a bare bordered cell on a visible grid is the honest vessel for that kind of record. There is no gloss to skim past and nothing dressed up to look like a result it is not.

We also keep the most consequential fact in the most prominent place: the boundary of the FDA approval. Tesamorelin is approved only for HIV-associated lipodystrophy, and everything else is off-label. A reader who takes nothing else from this site should take that. The rest is detail, cited and arranged so that anyone — a curious non-scientist or a researcher checking a number against its source — can follow the record without being sold anything.